News Contact Us

Biocon Biologics buys Pfizer Healthcare’s Chennai research facility

Author : Pankaj Singh | Published Date : 2019-09-25 

For the past few years, the pharmaceutical industry has witnessed an exponential growth across the globe. With various scientific innovations being conducted worldwide, companies have now started to expand their research capabilities by means of effective expansion strategies and acquisitions.

One such stride was made recently by Biocon Ltd., a leading biopharmaceutical company in Asia, when it revealed that its subsidiary, Biocon Biologics Ltd., has acquired Pfizer Healthcare’s biological research facility in Chennai for an undisclosed amount.

According to reliable sources, the buyout included the acquisition of R&D capital assets of a research facility spread over 60,000 sq. ft at the TICEL Bio Park in Chennai.

Speaking on the acquisition, Christiane Hamacher, CEO, Biocon Biologics, said that the Chennai-based R&D facility will allow their firm to grow its R&D capability and advance its motive to achieve its strategic long-term goals of fulfilling the requirements of millions of patients present across the globe.

Moreover, this investment will push the development of its biosimilars, taking it from lab to pilot scale, cites Hamacher.

Reportedly, the facility will house an early-stage innovation and research center that includes drug product formulation and analytical R&D laboratories as well as a pilot-scale R&D unit stocked with cell line development. Moreover, it is likely to be operational following post qualification and will accommodate around 250 scientists.

Sources cite that the purchase would offer a significant time advantage to the company and will develop the global advancements of its biosimilars portfolio.

Incidentally, Biocon has also been active in China, a promising market for pharmaceuticals. In a bid to enhance its presence, the company signed a supply and license agreement for the formulation of three Generic products with a subsidiary of China Medical System Holdings Ltd. (CMS).

Reportedly, the move comes at the foothills of the firm’s long-term strategy for generic formulations and grows its footprints in the Chinese pharmaceuticals market.

Speaking on which, Dr. Arun Chandavarkar, Joint Managing Director and CEO, Biocon, said that the company is thrilled to join CMS and this venture will enable their firm to retail its U.S. approved Generic Formulations to the Chinese patients, helping it to capitalize in the growing market.

Source Credit: https://www.moneycontrol.com/news/business/biocon-subsidiary-acquires-research-facility-from-pfizer-healthcare-4468051.html

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Skyrora to produce masks and sanitizers for UK amid COVID-19 crisis

Published Date: 2020-03-30         Author: Pankaj Singh

Skyrora, a Scotland based private space company, reportedly announced that it would start manufacturing health equipment for frontline workers in the United Kingdom, answering the call of the UK government as well as the National Health Service to help the country fight the growing spread of the cor... Read More

InterSystems launches a new version of InterSystems IRIS Data platform

Published Date: 2020-03-26         Author: Pankaj Singh

InterSystems, a U.S based software firm that focuses on helping consumers solve crucial interoperability, speed, and scalability problems efficiently, recently revealed its latest version of the InterSystems IRIS™ data solution. Reportedly, this comes as its third major launch of InterSyste... Read More

Twitter predicts a fall in ad sales but sees a surge in active users

Published Date: 2020-03-24         Author: Pankaj Singh

Amidst the effects of coronavirus, social network company Twitter withdrew its Q1 revenue outlook and estimated an operating loss as its ad sales suffer a massive downfall. However, this revenue report also displayed a massive surge in active users. According to the firm’s estimates, its fi... Read More

© 2020 Fractovia. All Rights Reserved